IJCRT.ORG ISSN : 2320-2882

INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

ADVANCEMENTS AND CHALLENGES IN DRUG DELIVERY SYSTEMS A COMPREHENSIVE REVIEW

Priyanka V Ingle[1]*, Kailas G Rathod[2], Bhagyashri S Gayke[3], Ganesh K Balaiya[4], Pooja B Divekar[5], Mayur R Waje[6]

[1]*-Assistant Professor, Department of Pharmacology, Dayanand College of Pharmacy, Latur M.S. India.

[2 & 3] Assistant Professor, Department of Quality Assurance Technique, Mangaldeep Institute of Pharmacy, Nipani, Chatrapati Sambhajinagar, M.S., India

[4 & 6-] Students, Mangaldeep Institute of Pharmacy, Nipani, Chatrapati Sambhajinagar, M.S., India.

[5-]Wani College of Pharmacy, Ganegaon, Ahmednagar, M.S., India.

Abstract:-

This review explores recent breakthroughs in drug delivery systems, spotlighting nanoparticles, liposome, and micelles as pivotal advancements. Nanotechnology emerges as a trans-formative force, facilitating targeted drug delivery and heightened bio-availability. The exploration extends to targeted delivery methodologies, embracing ligated-mediated targeting and stimulus-responsive systems to augment specificity. Nevertheless, challenges loom large, notably concerning bio-compatibility, and safety, underscoring the imperative for tailored solutions. Negotiating the intricate interplay among drug attributes, carrier properties, and biological barriers demands nuanced strategies. Regulatory hurdles and approval procedures present additional obstacles, warranting adherence to stringent protocols. Prospects for the future pivot on mitigating these constraints, envisioning personalized medicine paradigms, and assimilating cutting-edge technologies such as artificial intelligence and 3D printing. By surmounting these impediments, drug delivery systems stand poised to redefine therapeutic landscapes, promising enhanced treatment modalities and patient outcomes.

Keywords: Drug delivery systems, Nanotechnology, Targeted delivery, Future perspectives.

1. Introduction:-

The development of drug delivery technologies has had a profound impact on the pharmaceutical and healthcare industries worldwide(1). Improvements in drug delivery technologies have made it possible to precisely control drug release, improve targeting capabilities, and achieve better treatment effects(2). These methods range from straightforward oral tablets to complex nonparticipating carriers. This thorough analysis seeks to present a thorough examination of the most recent developments and related difficulties in drug delivery systems, providing insights into the revolutionary potential of these technologies and the obstacles that need to be removed before they are widely adopted. Interdisciplinary collaborations between pharmaceutical scientists, chemists, engineers, and doctors have propelled advancements in drug delivery methods(3). In particular, nanotechnology has changed the game in medication delivery by providing previously unheard-of possibilities for targeted therapy and controlled release. Among the creative nanocarriers that have been created to precisely encapsulate and deliver medications to particular tissues or cells are liposomes, dendrimers, micelles, and nanoparticles(4). These nanocarriers improve the solubility, bio-availability, and pharmacokinetic characteristics of pharmaceuticals while also shielding them from degradation and clearance(5). Therapeutic treatments have been further transformed by targeted drug delivery strategies, which allow for the selective distribution of medications to sick tissues while reducing systemic exposure and off-target consequences. Ligand-mediated targeting increases the concentration of drug-loaded carriers at the target site by taking advantage of the overexpression of particular receptors or antigens on the surface of sick cells(6).

Conversely, stimulus-responsive systems provide spatiotemporal control over therapeutic effects by utilizing environmental cues like pH, temperature, or enzyme activity to initiate drug release in the desired region. Beyond these impressive developments, drug delivery systems still confront significant obstacles that prevent them from being applied from the bench to the bedside. Significant obstacles include biocompatibility, immunogenicity, and safety issues(7). To reduce potential dangers, a comprehensive preclinical study and optimization are required. Drug delivery system design and optimization are made more difficult by the complex interactions among drug physicochemical properties, carrier features, and biological barriers. Customized strategies are needed to optimize therapeutic efficacy while reducing side effects(8).

The evolution of drug delivery systems spans several generations, each characterized by advancements in technology, materials, and methodologies aimed at enhancing therapeutic outcomes while minimizing side effects and improving patient compliance(9)(10).

First Generation; Tablets, capsules, and injections were the mainstays of the first generation of drug delivery systems. These traditional dosage formulations lacked precise control over the kinetics of drug administration and were dependent on passive drug release mechanisms(11). Second Generation; in the second generation, controlled-release formulations such as depot injections, transdermal patches, and sustained-release tablets were popular(12). These systems used a variety of techniques, including diffusion

barriers, matrix systems, and coating technologies, to extend the release of the medication. The goals of controlled-release formulations were to lessen dosage frequency, enhance patient convenience, and optimize medication pharmacokinetics. Third Generation; This generation saw the creation of sophisticated drug delivery devices that were more biocompatible and had better targeting abilities(13). Liposomes, nanoparticles, and micelles are a few examples of substances that can target particular tissues or cells, encapsulate medications, and shield them from disintegration. These methods reduce off-target effects, improve drug efficacy, and provide fine control over drug release kinetics(14). Fourth Generation: Sensitive or intelligent materials that can detect and react to changes in the physiological environment define the fourth generation of drug delivery systems(15). These systems include hydrogels, nanogels, and stimulus-responsive polymers that can release medication in response to changes in pH, temperature, enzyme activity, or external stimuli like magnetic fields or light. Systems of the fourth generation show potential for personalized treatment by enabling customized drug delivery based on individual patient needs and disease states(16). Fifth Generation; This group of researchers is at the forefront of drug delivery, concentrating on cutting-edge techniques including RNA interference, gene therapy, and targeted drug delivery through the use of biological vectors or nanomachines. These innovative strategies target particular genes, proteins, or cellular pathways implicated in the pathophysiology of disease in an effort to deliver therapeutic medicines with previously unheard-of accuracy(17)(18).



Fig. 1 Generation of Drug Delivery System

The clinical translation of novel medication delivery technology is further hampered by regulatory concerns and approval procedures(19). To guarantee the quality, safety, and efficacy of drug delivery systems, strict regulatory frameworks need strong preclinical data, clinical evidence of safety and efficacy, and adherence to Good Manufacturing Practices (GMP). As a result, negotiating the regulatory environment can take a lot of time and resources, which delays the release of promising medication delivery systems onto the market(20). The development of drug delivery methods has had a major impact on the pharmaceutical and therapeutic landscapes. Improvements in drug delivery technologies have made it possible to precisely

control drug release, improve targeting capabilities, and achieve better treatment effects. These methods range from straightforward oral tablets to complex nanoparticle-based carriers(15).

This thorough analysis seeks to present a thorough examination of the most recent developments and related difficulties in drug delivery systems, providing insights into the revolutionary potential of these technologies and the obstacles that need to be removed before they are widely adopted. Interdisciplinary collaborations between pharmaceutical scientists, chemists, engineers, and doctors have propelled advancements in drug delivery methods. In particular, nanotechnology has changed the game in medication delivery by providing previously unheard-of possibilities for targeted therapy and controlled release(21). Among the creative nanocarriers that have been created to precisely encapsulate and deliver medications to particular tissues or cells are liposomes, dendrimers, micelles, and nanoparticles. These nanocarriers improve the solubility, bioavailability, and pharmacokinetic characteristics of pharmaceuticals while also shielding them from degradation and clearance(22). By allowing the selective delivery of medications to sick tissues while reducing systemic exposure and off-target consequences, targeted drug delivery strategies have further transformed therapeutic interventions(23). By using the overexpression of particular receptors or antigens on the surface of sick cells, ligand-mediated targeting increases the concentration of drug-loaded carriers at the target location. On the other hand, stimulus-responsive systems provide spatiotemporal control over therapeutic effects by utilizing environmental cues like pH, temperature, or enzyme activity to initiate drug release at the targeted site. Despite these impressive developments, drug delivery systems still confront significant obstacles that prevent them from being applied from the bench to the bedside. Significant obstacles include biocompatibility, immunogenicity, and safety issues(6). To reduce potential dangers, a comprehensive preclinical study and optimization are required. Drug delivery system design and optimization are made more difficult by the complex interactions among drug physicochemical properties, carrier features, and biological barriers. Customized strategies are needed to optimize therapeutic efficacy while reducing side effects(24).

The clinical translation of novel medication delivery technology is further hampered by regulatory concerns and approval procedures. To guarantee the quality, safety, and efficacy of drug delivery systems, strict regulatory frameworks need strong preclinical data, clinical evidence of safety and efficacy, and adherence to Good Manufacturing Practices (GMP). As a result, negotiating the regulatory environment can take a lot of time and resources, which delays the release of promising medication delivery systems onto the market(19).

2. Advancements in Drug Delivery Systems:-

2.1 Nanotechnology in Drug Delivery:

Nanotechnology explores the development of materials at the nanoscale, encompassing natural, synthetic, or semi-synthetic polymers, lipids, and metallic substances. Nanoparticles (NPs) represent a significant aspect of this field, offering promise for targeted drug delivery(25). They enhance the bioavailability, distribution, and accumulation of therapeutics, particularly within diseased areas, while bolstering stability.

These colloidal systems serve as efficient vehicles for drug transport, elevating therapeutic effectiveness, minimizing toxicity and side effects, and shielding drugs from degradation by biological processes. This strategy facilitates precise control over the temporal and spatial release of therapeutics at disease sites(26). Initially, nanocarriers were utilized passively to improve drug delivery efficacy compared to traditional formulations(27). However, a novel approach has emerged, leveraging active targeting through the incorporation of specific ligands via conjugation or magnetic field strategies. Thus, nanotechnology stands poised to revolutionize drug formulations and delivery mechanisms, fostering innovation in the field. The result is more effective and precise drug delivery with reduced side effects(28).

Nanoparticles for Targeted Drug Delivery; Biopolymeric Nanoparticles; A variety of biopolymeric materials play essential roles in drug delivery systems, each offering distinct properties and applications, as discussed below(29).

Chitosan: Chitosan, known for its muco-adhesive properties, can effectively interact with tight epithelial junctions. Consequently, nanomaterials based on chitosan find extensive use in sustained drug release systems across various epithelial surfaces, including buccal, intestinal, nasal, ocular, and pulmonary routes. For instance, Silva et al. formulated and assessed the effectiveness of chitosan, sodium tripolyphosphate, and hyaluronic acid nanoparticles in delivering the antibiotic ceftazidime to the eye. These nanoparticles exhibited mucoadhesive properties, ensuring prolonged release of the antibiotic and enhancing its retention in the eyes, thereby potentially extending the drug's therapeutic duration. Notably, these nanoparticles demonstrated biocompatibility and preserved antibacterial activity, making them promising candidates for ocular drug delivery(30).

Pistone et al. developed nanoparticles comprising chitosan, alginate, and pectin for oral drug administration. The biocompatibility of these formulations was evaluated based on their solubility in saliva and cytotoxicity in oral cell lines. While alginate nanoparticles exhibited stability in saliva, chitosan nanoparticles demonstrated superior cytocompatibility. However, the presence of Zn^{2+} as a cross-linking agent led to cytotoxicity in some formulations. Each nanoparticle formulation presented distinct advantages and limitations for oral drug delivery, necessitating further refinement(31).

Another study by Jain and Jain investigated the release profile of 5-fluorouracil (5-FU) from hyaluronic acid-coated chitosan nanoparticles for oral administration targeting the gut. These nanoparticles exhibited controlled release kinetics, protecting 5-FU from premature release in the stomach and small intestine. The localized drug concentration potentially enhances anti-tumor efficacy while minimizing systemic toxicity in colon cancer treatment(32).

Alginate: Another biopolymer utilized in drug delivery is alginate, characterized by terminal carboxyl groups and strong mucoadhesive properties. Patil and Devarajan developed insulin-containing alginate nanoparticles with nicotinamide as a permeation enhancer for sublingual administration in diabetic rats.

These nanoparticles demonstrated high pharmacological and bioavailability profiles, indicating their potential as carriers for sublingual insulin delivery in diabetes management(33).

These examples underscore the versatility and potential of biopolymeric nanoparticles in advancing drug delivery systems across various administration routes and therapeutic applications(34).

Liposomes and Micelles;

Liposomes, discovered by Alec Bangham in 1960, play a crucial role in the pharmaceutical and cosmetics industries, serving as carriers for diverse molecules and representing one of the most extensively studied systems for drug delivery. These vesicles, ranging from 50 to 450 nm in size, are composed of phospholipids and steroids, adopting a spherical structure. They stand as a fundamental formulation strategy for enhancing drug delivery, owing to their resemblance to cell membranes and their capacity to encapsulate drugs. Liposomes offer several advantages, including the stabilization of therapeutic compounds, improvement of bio-distribution, compatibility with hydrophilic and hydrophobic drugs, and biocompatibility and biodegradability. They are categorized into four types: conventional liposomes, featuring a lipid bilayer encapsulating an aqueous core; PEGylated liposomes, where polyethylene glycol (PEG) is added to achieve steric stabilization; ligand-targeted liposomes, adorned with ligands such as antibodies, carbohydrates, or peptides for targeted delivery; and theranostic liposomes, which combine elements of the previous types, typically comprising nanoparticles with targeting, imaging, and therapeutic components(35)(36).



Fig. 2. Liposome and Micelle in Drug Delivery System

Polymeric micelles are nanostructures composed of amphiphilic block copolymers that self-assemble into a core-shell structure in aqueous solutions. The hydrophobic core of these micelles can encapsulate hydrophobic drugs such as camptothecin, docetaxel, and paclitaxel, while the hydrophilic shell ensures water solubility and stabilizes the core. Typically under 100 nm in size with a narrow distribution to avoid rapid renal excretion, polymeric micelles accumulate in tumour tissues via the enhanced permeability and retention (EPR) effect, aided by their polymeric shell that minimizes nonspecific interactions with biological

components. This property makes them promising candidates for delivering hydrophobic drugs, enhancing stability and bioavailability. Polymeric micelles are synthesized through two main approaches: solvent-based direct dissolution of the polymer followed by a dialysis process, or precipitation of one block by adding a solvent. Factors such as the size of the hydrophobic chain in the amphiphilic molecule, concentration of amphiphiles, solvent system, and temperature influence micelle formation. The assembly of micelles begins when the concentration reaches the critical micelle concentration (CMC), at which point amphiphilic molecules aggregate(37). Drugs can be loaded into polymeric micelles using three common methodologies: direct dissolution, solvent evaporation, and dialysis. In the direct dissolution process, the copolymer and drugs self-assemble in the water medium to form drug-loaded micelles. In the solvent evaporation process, the copolymer and drug are dissolved in a volatile organic solvent, and in the dialysis process, both the drug solution and copolymer in the organic solvent are combined in a dialysis bag and dialyzed to form micelles(38).

2.2 Biomaterials in Drug Delivery;

The utilization of biomaterials offers significant enhancements across various drug delivery modalities, including injectable, oral, ocular, pulmonary, nasal, and transdermal routes. Examples of biomaterials encompass metals, glass, ceramics, and ocular materials, which find applications not only in drug delivery but also in orthopedic implants, contact lenses, heart valves, and pacemakers. Biomaterials are broadly classified into naturally derived and synthetically derived categories, with synthetic polymers being the predominant choice for drug delivery systems. Upon introduction into the body, polymeric drugs undergo a transition in morphology from a solution to a gel state. It's crucial to recognize that these gel formulations exhibit diverse responses to stimuli such as temperature, ultraviolet radiation, ions, and variations in pH levels(39)(40).

Hydrogels: Made of hydrophilic polymers, hydrogels are three-dimensional networks that can absorb a lot of water or biological fluids without compromising their structural integrity. Their high water content and adjustable characteristics make them the perfect medium for medication encapsulation and release. The kinetics of drug release can be precisely controlled by hydrogels because they can be made to react to a variety of stimuli, including pH, temperature, and enzymes(41).

Polymers and delivery systems based on Polymers: Both synthetic and natural polymers are effective medication delivery vehicles. Poly (lactic-co-glycolic acid) (PLGA) and polyethylene glycol (PEG) are examples of synthetic polymers that have specific features such as regulated release kinetics, biocompatibility, and biodegradability. Targeted drug delivery and prolonged release are made possible by a variety of formulations found in polymer-based delivery systems, including micelles, dendrimers, and nanoparticles(42).

Biodegradable Implants: This method of long-term medication administration seems promising. Usually composed of biocompatible polymers like polylactic acid (PLA) and polylactic-co-glycolic acid (PLGA),

these implants break down gradually in vivo to release therapeutic chemicals over time. They offer advantages in terms of decreased systemic toxicity and enhanced patient compliance. They are especially well-suited for localized distribution and can be customized to match the degradation rate with the intended release profile(43).

3. Challenges in Drug Delivery Systems:

Drug delivery systems face significant obstacles due to biological barriers, which hinder the effective administration of therapeutic medicines to specific locations inside the body. The blood-brain barrier (BBB) and mucosal barriers are two of these barriers that are particularly significant obstacles to ensuring successful drug delivery(44).

The blood-brain barrier (BBB) strictly controls the entry of molecules into the central nervous system (CNS), acting as a barrier of defence between the bloodstream and the brain parenchyma. The blood-brain barrier (BBB) limits the passage of medications meant to treat neurological conditions, including brain tumours and Alzheimer's disease, despite being vital for preserving brain homeostasis. It is still exceedingly difficult to get beyond the BBB's selective permeability, which calls for creative solutions like targeted delivery methods and drug carriers based on nanoparticles to help get drugs past the barrier(45).

Mucosal barriers present difficulties for drug absorption and distribution since they line a variety of epithelial surfaces in the body, such as the gastrointestinal, respiratory, ophthalmic, and genitourinary tracts. These obstacles may reduce the efficacy of topical treatments, mucosal vaccinations, and medications taken orally. The creation of mucoadhesive nanoparticles, penetration enhancers, and innovative drug delivery systems to improve drug absorption across mucosal surfaces are some strategies to get past mucosal barriers(46).

In order to overcome these biological hurdles, multidisciplinary research projects and cutting-edge drug delivery systems that can get beyond these barriers without sacrificing therapeutic efficacy or causing unnecessary side effects are required. It is imperative that these obstacles be overcome in order to progress the treatment of several illnesses and enhance patient outcomes.

3.2 Regulatory and Commercialization Challenges;

Regulatory and commercialization challenges represent significant hurdles in the development and adoption of novel drug delivery systems, encompassing aspects such as the approval process and considerations of cost-effectiveness and scalability(10).(41)

Approval Process for Novel Delivery Systems;

The approval process for novel drug delivery systems involves stringent regulatory requirements to ensure the safety, efficacy, and quality of pharmaceutical products. Manufacturers must adhere to guidelines set forth by regulatory agencies such as the Food and Drug Administration (FDA) in the United States or the European Medicines Agency (EMA) in Europe. Novel delivery systems often require extensive preclinical

and clinical testing to demonstrate their therapeutic benefits and safety profiles compared to conventional formulations(47). Challenges in this process include navigating complex regulatory pathways, addressing concerns related to product quality and stability, and meeting requirements for manufacturing consistency and reproducibility. Additionally, the regulatory landscape may vary between regions, necessitating careful consideration of global regulatory requirements for market approval(48).

Cost-effectiveness and Scalability;

Cost-effectiveness and scalability are critical considerations in the development and commercialization of drug delivery systems. While novel delivery technologies may offer improved therapeutic outcomes, they must also demonstrate economic viability and scalability to be adopted widely in clinical practice. Challenges arise in optimizing manufacturing processes to ensure cost-efficient production while maintaining product quality and consistency(49). Factors such as raw material costs, manufacturing complexity, and scalability of production infrastructure influence the overall cost-effectiveness of drug delivery systems. Additionally, healthcare payers and providers seek evidence of cost-effectiveness and value proposition when considering the adoption of new therapies. Thus, developers of novel drug delivery systems must conduct comprehensive economic evaluations and demonstrate favourable cost-effectiveness profiles compared to existing treatment options. Furthermore, considerations of scalability involve assessing the ability to ramp up production to meet market demand and ensuring supply chain resilience to avoid disruptions in drug availability.

Innovative medicine delivery system development and commercialization require skilfully negotiating regulatory processes as well as resolving issues with cost-effectiveness and scalability. To overcome these obstacles and effectively and economically provide patients with novel therapies, cooperation between industry, regulatory bodies, and healthcare stakeholders is crucial(50).

4. Solutions and Future Perspectives:

Solutions and future perspectives in the realm of drug delivery systems present promising avenues for overcoming current challenges and discovering new opportunities for therapeutic innovation(51). By addressing existing limitations and harnessing emerging technologies, researchers and pharmaceutical firms can pave the path towards enhanced drug delivery strategies and improved patient outcomes. A key solution lies in the development of targeted delivery systems capable of precisely delivering therapeutic agents to specific tissues or cells within the body. Targeted drug delivery minimizes off-target effects and maximizes therapeutic efficacy, potentially reducing the required dosage and mitigating side effects. This approach involves employing various targeting mechanisms, such as ligand-receptor interactions, antibody-mediated targeting, and stimuli-responsive drug release systems. Moreover, advancements in nanotechnology and biomaterials offer promising solutions for surmounting biological barriers and enhancing drug delivery efficiency. Nanoparticle-based drug carriers, including liposomes, polymeric nanoparticles, and dendrimers, facilitate controlled drug release, improved cellular uptake, and targeted delivery to disease sites. Additionally, biomaterials engineered to mimic the extracellular matrix or cellular microenvironments can enhance tissue regeneration and promote therapeutic efficacy in regenerative medicine applications(52).

Innovations in drug delivery systems also encompass the integration of smart technologies and personalized medicine approaches. Smart drug delivery systems, equipped with sensors and actuators, enable real-time monitoring of drug release kinetics and patient response, facilitating personalized adjustments to dosage regimens. Furthermore, advancements in pharmacogenomics and precision medicine enable the customization of drug therapies based on individual genetic profiles, optimizing treatment outcomes and reducing adverse reactions(53)(54).

Looking ahead, the convergence of artificial intelligence, machine learning, and big data analytics holds immense potential for revolutionizing drug delivery systems. These technologies can streamline the design of novel drug carriers, predict drug-target interactions, and optimize treatment protocols, leading to more efficient drug delivery strategies and accelerated drug development timelines(55).

5. Conclusion:-

In conclusion, this comprehensive review delves into the recent advancements and challenges within the realm of drug delivery systems. It illuminates breakthroughs in various delivery modalities, including nanoparticles, liposomes, and polymeric micelles, highlighting their transformative potential in enhancing drug efficacy and targeting specificity. Despite the promising advancements, significant challenges persist, such as biocompatibility concerns, regulatory hurdles, and scalability issues. However, by leveraging emerging technologies and innovative strategies, such as personalized medicine approaches and smart drug delivery systems, these challenges can be effectively addressed. Looking forward, the future of drug delivery systems holds immense promise, with the potential to revolutionize therapeutic landscapes and usher in an era of tailored treatments, improved patient outcomes, and enhanced quality of life.

6. References:-

1. Tibbitt MW, Dahlman JE, Langer R. Emerging Frontiers in Drug Delivery. J Am Chem Soc. 2016;138(3):704–17.
2. Gaikwad AS, Waje MR, Tile VS PP. Targeted Drug Delivery–From Magic Bullet to Nanomedicine. J Xidian Univ. 2023;17(8):1540–51.
3. Giramkar AA, Gaikwad AS, Hole BR PV. Microsponge Drug Delivery System-A Review. PENSEE. 2020;50(12):1774–86.
4. Lombardo D, Kiselev MA, Caccamo MT. Smart Nanoparticles for Drug Delivery Application: Development of Versatile Nanocarrier Platforms in Biotechnology and Nanomedicine. J Nanomater. 2019;2019.
5. Zhang A, Meng K, Liu Y, Pan Y, Qu W, Chen D, et al. Absorption, distribution, metabolism, and excretion of nanocarriers in vivo and their influences. Adv Colloid Interface Sci. 2020;284.
6. Vyas SP, Singh A, Sihorkar V. Ligand-receptor-mediated drug delivery: An emerging paradigm in cellular drug targeting. Crit Rev Ther Drug Carrier Syst. 2001;18(1):1–76.

7. Helal NA, Osami A, Helmy A, McDonald T, Shaaban LA, Nounou MI. Non-viral gene delivery systems: Hurdles for bench-to-bedside transformation. Pharmazie. 2017;72(11):627–51.

8. Finbloom JA, Sousa F, Stevens MM, Desai TA. Engineering the drug carrier biointerface to overcome biological barriers to drug delivery. Adv Drug Deliv Rev. 2020;167:89–108.

9. Laffleur F, Keckeis V. Advances in drug delivery systems: Work in progress still needed? Int J Pharm. 2020;590.

10. Vargason AM, Anselmo AC, Mitragotri S. The evolution of commercial drug delivery technologies. Nat Biomed Eng. 2021;5(9):951–67.

11. Jain KK. An Overview of Drug Delivery Systems. Methods Mol Biol. 2020;2059:1–54.

12. Yun YH, Lee BK, Park K. Controlled Drug Delivery: Historical perspective for the next generation. J Control Release. 2015;219:2–7.

13. Crommelin DJA, Florence AT. Towards more effective advanced drug delivery systems. Int J Pharm. 2013;454(1):496–511.

14. Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021;20(2):101–24.

15. Adepu S, Ramakrishna S. Controlled drug delivery systems: Current status and future directions. Molecules. 2021;26(19).

16. Hajebi S, Rabiee N, Bagherzadeh M, Ahmadi S, Rabiee M, Roghani-Mamaqani H, et al. Stimulus-responsive polymeric nanogels as smart drug delivery systems. Acta Biomater. 2019;92:1–18.

17. A. M. Implementation of artificial intelligence in biotechnology for rapid drug discovery and enabling personalized treatment through vaccines and therapeutic products.

18. Mohapatra SS, Ranjan S, Dasgupta N, Mishra RK, Thomas S. Characterization and Biology of Nanomaterials for Drug Delivery: Nanoscience and Nanotechnology in Drug Delivery. Charact Biol Nanomater Drug Deliv Nanosci Nanotechnol Drug Deliv. 2018;1–682.

19. Wen H, Jung H, Li X. Drug Delivery Approaches in Addressing Clinical Pharmacology-Related Issues: Opportunities and Challenges. AAPS J. 2015;17(6):1327–40.

20. Ni J, Lin X, Shen XS. Toward Edge-Assisted Internet of Things: From Security and Efficiency Perspectives. IEEE Netw. 2019;33(2):50–7.

21. Bertoni S, Dolci LS, Albertini B, Passerini N. Spray congealing: A versatile technology for advanced drug-delivery systems. Ther Deliv. 2018;9(11):833–45.

22. Huda S, Alam MA, Sharma PK. Smart nanocarriers-based drug delivery for cancer therapy: An innovative and developing strategy. J Drug Deliv Sci Technol. 2020;60.

23. Glassman PM, Myerson JW, Ferguson LT, Kiseleva RY, Shuvaev V V., Brenner JS, et al. Targeting drug delivery in the vascular system: Focus on endothelium. Adv Drug Deliv Rev. 2020;157:96–117.

24. Muro S. Challenges in design and characterization of ligand-targeted drug delivery systems. J Control Release. 2012;164(2):125–37.

25. Park K. Facing the truth about nanotechnology in drug delivery. ACS Nano. 2013;7(9):7442–7.

26. Aqil F, Munagala R, Jeyabalan J, Vadhanam M V. Bioavailability of phytochemicals and its enhancement by drug delivery systems. Cancer Lett. 2013;334(1):133–41.

27. Das RP, Gandhi V V., Singh BG, Kunwar A. Passive and Active Drug Targeting: Role of Nanocarriers in Rational Design of Anticancer Formulations. Curr Pharm Des. 2019;25(28):3034–56.

28. Serov N, Vinogradov V. Artificial intelligence to bring nanomedicine to life. Adv Drug Deliv Rev. 2022;184.

29. Bera H, Hossain CM, Saha S. Biopolymer-Based Nanomaterials in Drug Delivery and Biomedical Applications. Biopolym Nanomater Drug Deliv Biomed Appl. 2021;1–603.

30. Ryu JH, Choi JS, Park E, Eom MR, Jo S, Lee MS, et al. Chitosan oral patches inspired by mussel adhesion. J Control Release. 2020;317:57–66.

31. Pistone S, Goycoolea FM, Young A, Smistad G, Hiorth M. Formulation of polysaccharide-based nanoparticles for local administration into the oral cavity. Eur J Pharm Sci. 2017;96:381–9.

32. Kumar S, Sharma B, Thakur K, Bhardwaj TR, Prasad DN, Singh RK. Recent Advances in the Development of Polymeric Nanocarrier Formulations for the Treatment of Colon Cancer. Drug Deliv Lett. 2018;9(1):2–14.

33. Patra JK, Das G, Fraceto LF, Campos EVR, Rodriguez-Torres MDP, Acosta-Torres LS, et al. Nano based drug delivery systems: Recent developments and future prospects. J Nanobiotechnology. 2018;16(1).

34. Wu J, Shaidani S, Theodossiou SK, Hartzell EJ, Kaplan DL. Localized, on-demand, sustained drug delivery from biopolymer-based materials. Expert Opin Drug Deliv. 2022;19(10):1317–35.

35. Elizondo E, Moreno E, Cabrera I, Córdoba A, Sala S, Veciana J, et al. Liposomes and other vesicular systems: Structural characteristics, methods of preparation, and use in nanomedicine. Prog Mol Biol Transl Sci. 2011;104:1–52.

36. Sathyamoorthy N, Dhanaraju MD. Shielding therapeutic drug carriers from the mononuclear phagocyte system: A review. Crit Rev Ther Drug Carrier Syst. 2016;33(6):489–567.

37. Kaur J, Mishra V, Singh SK, Gulati M, Kapoor B, Chellappan DK, et al. Harnessing amphiphilic polymeric micelles for diagnostic and therapeutic applications: Breakthroughs and bottlenecks. J

Control Release. 2021;334:64–95.

38. Ghezzi M, Pescina S, Padula C, Santi P, Del Favero E, Cantù L NS. Polymeric micelles in drug delivery: An insight of the techniques for their characterization and assessment in biorelevant conditions.

39. Colilla M, Izquierdo-Barba I, Vallet-Regí M. Novel biomaterials for drug delivery. Expert Opin Ther Pat. 2008;18(6):639–56.

40. Santos LF, Correia IJ, Silva AS, Mano JF. Biomaterials for drug delivery patches. Eur J Pharm Sci. 2018;118:49–66.

41. Singh MR, Patel S, Singh D. Natural polymer-based hydrogels as scaffolds for tissue engineering. Nanobiomaterials Soft Tissue Eng Appl Nanobiomaterials. 2016;231–60.

42. Makadia HK, Siegel SJ. Poly Lactic-co-Glycolic Acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers (Basel). 2011;3(3):1377–97.

43. Alsaab HO, Alharbi FD, Alhibs AS, Alanazi NB, Alshehri BY, Saleh MA, et al. PLGA-Based Nanomedicine: History of Advancement and Development in Clinical Applications of Multiple Diseases. Pharmaceutics. 2022;14(12).

44. Upadhyay RK. Drug delivery systems, CNS protection, and the blood brain barrier. Biomed Res Int. 2014;2014.

45. Achar A, Myers R, Ghosh C. Drug delivery challenges in brain disorders across the blood–brain barrier: Novel methods and future considerations for improved therapy. Biomedicines. 2021;9(12).

46. Huang M, Zhang M, Zhu H, Du X, Wang J. Mucosal vaccine delivery: A focus on the breakthrough of specific barriers. Acta Pharm Sin B. 2022;12(9):3456–74.

47. Arote KS, Salade DA, Patil N V. A Brief Review on Regulatory Affairs: Ensuring Compliance, Safety, and Market Access. 2023;1:22–30.

48. Zylberberg C, Matosevic S. Pharmaceutical liposomal drug delivery: a review of new delivery systems and a look at the regulatory landscape. Drug Deliv. 2016;23(9):3319–29.

49. Halwani AA. Development of Pharmaceutical Nanomedicines: From the Bench to the Market. Pharmaceutics. 2022;14(1).

50. Hudson J, Khazragui HF. Into the valley of death: Research to innovation. Drug Discov Today. 2013;18(13–14):610–3.

51. Lorscheider M, Gaudin A, Nakhle J, Veiman KL, Richard J, Chassaing C. Challenges and opportunities in the delivery of cancer therapeutics: Update on recent progress. Ther Deliv. 2021;12(1):55–76.

52. Dristant U, Mukherjee K, Saha S, Maity D. An Overview of Polymeric Nanoparticles-Based Drug Delivery System in Cancer Treatment. Technol Cancer Res Treat. 2023;22.

53. Cicha I, Priefer R, Severino P, Souto EB, Jain S. Biosensor-Integrated Drug Delivery Systems as New Materials for Biomedical Applications. Biomolecules. 2022;12(9).

54. Manikkath J, Subramony JA. Toward closed-loop drug delivery: Integrating wearable technologies with transdermal drug delivery systems. Adv Drug Deliv Rev. 2021;179.

55. Sahu M, Gupta R, Ambasta RK, Kumar P. Artificial intelligence and machine learning in precision medicine: A paradigm shift in big data analysis. Prog Mol Biol Transl Sci. 2022;190(1):57–100.